Amsterdam, April 1st 2014 – Royal Dutch Shell and the Dutch NGO PharmAccess have signed an agreement to work together to improve access to affordable, quality healthcare in Africa. Shell and PharmAccess will combine their knowledge, skills and expertise and cooperate on a range of existing and new sustainable healthcare initiatives. It is hoped that these initiatives could be replicated on a larger scale, benefitting a growing number of people in Africa.
This strategic partnership builds upon a longstanding working relationship between PharmAccess and Shell to provide access to quality healthcare in resource constrained areas. Shell and PharmAccess share a vision that emphasizes the importance of healthcare as a public good, from a socio-economic, public health and economic perspective. Both believe in the power of innovation and the importance of private sector healthcare involvement to achieve sustainable and affordable health care delivery, tailored to the needs of each community.
PharmAccess employs an integral and innovative approach to improve access to quality health care. By combining clinical standards, loans for healthcare providers, health insurance, innovative technologies (including mHealth) and in-depth impact research we simultaneously stimulate the demand for and supply of healthcare services. This model helps to lower the risk and increase trust among patients, doctors, insurance companies, healthcare providers, banks, government and international investors, thereby increasing their willingness to pay for or invest in health care in Africa and scale up functioning health systems.
Alistair Fraser, Vice President, Shell Health, said: “Shell has a strong commitment to improving access to quality healthcare in the communities where we operate. This partnership provides us with the chance to combine our knowledge and resources with PharmAccess’ extensive experience in Africa.”
Monique Dolfing, Chief Operating Officer, PharmAccess, said: ”Our mission is to provide better access to quality healthcare for all in Africa. Shell’s presence on the continent, and their interests in the field of healthcare, make them an important partof this effort. We believe that by sharing networks and expertise, together we can create innovative, sustainable and scalable models of quality health care.”
Shell and PharmAccess have identified several project opportunities for collaboration that have the potential to be scaled up. One example is in Ogun State in Nigeria, where Shell and the Ogun State Ministry of Health are jointly developing a community health insurance scheme to promote access to healthcare for low-income people. PharmAccess has developed a healthcare package tailored to the needs of the population and introduced a quality improvement program to greatly improve the standard of health services. This public-private model has already generated interest from other parties in financing further development of the program in Ogun State and in other states in Nigeria.
Click here for the announcement on Shell’s website.
Contact for the press:
PharmAccess communications: Laurens Pels, firstname.lastname@example.org,
+31 6 1920 6238
About the organizations:
Royal Dutch Shell plc is incorporated in England and Wales, has its headquarters in The Hague and is listed on the London, Amsterdam, and New York stock exchanges. Shell companies have operations in more than 70 countries and territories with businesses including oil and gas exploration and production; production and marketing of liquefied natural gas and gas to liquids; manufacturing, marketing and shipping of oil products and chemicals and renewable energy projects. For further information, visit www.shell.com.
The PharmAccess Group, a Dutch not-for-profit organization dedicated to improving access to quality health care for people in sub-Saharan Africa. The PharmAccess Group mobilizes public and private resources for the benefit of patients and doctors through clinical quality standards, loans for clinics, health insurance and impact research. We leverage donor contributions to increase trust in the health system, reduce risk and lower transaction costs, paving the way for private investments. For further information, visit www.pharmaccess.org